**Canadian Task Force
on Preventive Health Care
e:** info@canadiantaskforce.ca
**w:** www.canadiantaskforce.ca

**Canadian Task Force
on Preventive Health Care**

## Table 8. False Positive and False Positive Biopsy Calculations (Breast Cancer Screening Cohort) - Revised

| False Positives and Unnecessary Biopsies from an Estimated Cohort of Women in a Breast Screening Program[1] | | | | |
|---|---|---|---|---|
| | 40-49 years | 50-59 years | 60-69 years | 70-74 years |
| Per 1,000 women screened (over a median of 7 years- 3 cycles) [2] | | | | |
| FP Mammography | 294 | 294 | 256 | 219 |
| Biopsies on FP | 43 | 37 | 35 | 30 |
| | | | | |
| | 40-49 years | 50-59 years (M) | 60-69 years | 70-74 years |
| Per one death prevented‡ (Short-Case Accrual: over a median screening period of 7 years, with median follow-up of 23 years- 8 cycles) [3] | | | | |
| NNS (95%CI) | 1,724 (1,176 to 3,704) | 1,333 (909 to 2,857) | 1,087 (741 to 2,326) | 645 (441 to 1,389) |
| FP Mammography | 1,138 | 869 | 628 | 319 |
| Biopsies on FP | 156 | 107 | 82 | 44 |

M: Moderate baseline risk

*The data is presented as the weighted average.

‡ Used Relative Risk estimates for 'all ages' and applied to each age sub-group which resulted in the calculation for NNS. See footnote in Table 1 of Guideline document for further explanations.

[1]The data is used to approximate a cohort of women entering the screening program. Although assumed, but not confirmed, the 'initial screen' in the CPAC report is the first screen documented in the database, and may not necessarily be the first 'true' screen of a woman. This is especially true for data originating from Alberta.

[2] Data is estimated for 3 cycles over a median of 7 years, assuming women get screened every 2-3 years. The median of 7 years is reflective of the median screening period of the included studies included in the meta-analysis for short-case breast cancer mortality. Calculation: Initial + 2 (Subsequent).

[3] Data is estimated for 8 cycles over a median of 23 years, assuming women get screened every 2-3 years. The median of 23 years is reflective of the entire follow-up time of the studies included in the meta-analysis for short-case breast cancer mortality. Calculation: Initial + 7 (Subsequent).